Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced positive top-line results from its 168 patient Phase 2a clinical trial of AZ-104 (Staccato(R) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE